the mental health trigger tool concept and development a/prof chua hong choon, chief executive...
TRANSCRIPT
The Mental Health Trigger ToolConcept and Development
A/Prof Chua Hong Choon, Chief Executive OfficerDr Sajith Sreedharan, Consultant (General Psychiatry)
Apr 2014
Disclosures: None
S’pore Healthcare Services
Mental Health Trigger Tool
Prevalence Studies of AEs
Overview of IMH
The Little Red Dot
AGENDA
• Location: An island in the heart of Southeast Asia, between Malaysia and
Indonesia• Area: 710.3 sq km• Climate: Tropical 23 – 31 Degrees Celsius• Population: 5.18 million • Life Expectancy: 81.48 years• Ethnic Groups: Chinese 74%, Malay 13%, Indian 9%, other
ethnicities 3%• Religions: Buddhism, Islam, Christianity, Taoism and Hinduism
Republic of Singapore
Singapore HealthcareServices & Facilities
Primary Healthcare Services
18Polyclinics
2,400 Private Clinics
Hospital Services
7Public
Hospitals
5 Acute General
Hospitals
1Women’s & Children’s Hospital
1Tertiary
Psychiatric Hospital
6National Specialty Centres
Institute of Mental Health
About Us
• Singapore’s only tertiary psychiatric institution• National centre part of the NHG Regional Health System• 2010 beds• Looks after most severe cases • Provides acute and long-term care
554 Daily Visits
(Outpatient Clinics Only)
22Daily Admissions*
1,745 Inpatients*
37,240 Outpatients
(ES Included)
568 Acute
1,177Long-stay
(as of 2013)* Excluding 23-hr observation ward
Top 5 Disorders Seen in 2012
INPATIENT DISCHARGES
1. Schizophrenic Disorders
2. Depressive Disorder
3. Reaction to Severe Stress 4. Mental and behavioural
disorders due to use of opioids
5. Unspecified nonorganic psychosis
OUTPATIENT VISITS
1. Schizophrenic Disorders
2. Depressive Disorder
3. Reaction to Severe Stress
4. Other Anxiety Disorders 5. Unspecified nonorganic
psychosis
• Patient-Centred Care • Systems Thinking• Learning Organisation • Staff Engagement
4 Principles
IMH Quality and Safety Framework
DET
ECTI
ON
VALI
DATI
ON
ANAL
YSIS
IMPR
OVE
MEN
T
Serious Reportable
Event
Frequent Adverse Events
Near Misses
General Feedback
SPREAD CHANGE
Monitor and Evaluate Change
Facilitators, Training etc
Top Clinical Risks
Assault Choking
Falls Restraints
Suicide
Patients defaulting on care
Major permanent injury or inpatient death as a result of these incidents
Deterioration of patients’ mental health status leading to potential harm to self and others as a result of patients defaulting psychiatric clinic follow-ups
Reducing Bedtime Sedatives
*PRN is a medication that is ordered by a practitioner to be administered on an “As Needed” basis according to written parameters of a practitioner.#Sedatives is a substance that induces sedation by reducing irritability or excitement.
Focus
Target
Interventions
Sustain & Spread
Frequent usage of PRN* sedatives in Geriatric Psychiatry wards
To reduce the administration rate of PRN* bedtime sedatives** by nurses in an acute psycho-geriatric ward by 30% in 6 months.
•Make environment more conducive for sleep : change shift-handover location •Pharmacological education to enhance nurses’ understanding •Patient education to address lack of knowledge•Introduce sleep monitoring chart to track patients’ sleep patterns
Gains sustained & interventions successfully spread to another geriatric psychiatry ward
51% Reduction
Average Administration Rate of Bedtime PRN Sedatives Per Week
Focus
Target
Sustain & Spread
Tracking Discharged PatientsCare integration & treatment compliance for patients with Schizophrenia & Delusional Disorders
Increased specialist clinic attendance rate of recently discharged IMH patients by 10% in Year 1 as compared to baseline
Interventions
•Use of risk and needs assessment and stratification
•Case Management and Case Tracking
•Integrating systems (between IMH and Community Partners) through right-siting
Sharing project interventions & results with other public hospitals and community partners for spread
DETECTING HARMAdverse Events Studies
Adverse Events Studies 2007/2010 1st stage against a
list of 18 triggers (from Harvard Medical Practice Study) as flags for potential adverse events that require further review.
2nd stage by clinician on criteria positive cases to determine occurrence, disability, causation and preventability of AE
Double review for inter-rater reliability done for 10% RF1 and RF2
• Metrics/Unit of measurement o is adverse event, o measure disability as estimate of severity,o measure preventability as ascertained by clinician reviewers.
Developing a Mental Health Trigger Tool
Mental Health Trigger Tool (MHTT)
A tool to effectively Identify Harm or Adverse Events (AE) in a mental health setting and
monitor their rate over time
Most common methods of identifying and monitoring Harm or AE
Time andresourceintensive
Voluntary Reporting
Comprehensive File Review
• <20 % reported
• 90-95% no harm to patients
Is there a more efficient method?
• Global Trigger tool and Trigger tool Methodology- Developed by Institute of Health Improvement (IHI)
“ a retrospective review of randomly selected patient records using triggers (clues) to detect AE”
IHI Global Trigger Tool
Concentrate on identifying Harm or AE, not errors Only AE through acts of commission, not omission Preventability not a criterion Severity is rated based on NCC MERP index
Harm defined as “Unintended physical injury resulting from or contributed to by medical care that requires additional montioring, treatment or hospitalisation
or that results in death”
The GTT Review Methodology
• Random set of patient records• Trained Reviewers - Two Primary Reviewers - One physician Reviewer Excludes Psychiatric and Rehab Patients
Trigger Modules : • Cares (15) e.g. Transfusion of blood• Medication (13) e.g. Abrupt medication stop• Surgical • Intensive Care • Perinatal • Emergency Department
Trigger tool in Mental Health
• IHI Trigger Tool for Measuring Adverse Drug Events in a Mental Health Setting
• 30 triggers• Sodium Polystyrene Sulfonate• C. difficile Positive Stool• Vitamin K Only addresses AE due to medications Not comprehensive / specific enough May not be applicable to all mental health settings
Singapore Mental Health Trigger Tool Project
Developing Trigger Tool Exculsively for Mental Health
Setting
Resource and Time Efficient
Comprehensive
Applicable Internationally
• MHTT Project Steering Committee
• Workgroup to Develop the MHTT
• Team of Reviewers
• Project Plan / Timeline
Planning(Feb/Mar 13)
Preparation(Apr/May 13)
Dev of MHTT(Jun/Jul 13)
POC trial(Aug/Sep13)
MHTT Project
MHTT Project Team
• Preliminary review of literatureIHI White Paper on GTT
• Facilitated trainingA facilitated discussion and training on review of the charts were done with an experienced GTT chart reviewer and physician reviewer
Planning(Feb/Mar 13)
Preparation(Apr/May 13)
Dev of MHTT(Jun/Jul 13)
POC trial(Aug/Sep13)
MHTT Project
• Comprehensive Literature Review• Focus Group• Clinical Advisory Panel• Modified Delphi Panel
Planning(Feb/Mar 13)
Preparation(Apr/May 13)
Dev of MHTT(Jun/Jul 13)
POC trial(Aug/Sep13)
MHTT Project
Comprehe-nsive
Literature Review
FocusGroup
ClinicalAdvisory
Panel
ModifiedDelphi Panel
Trigger List
Development of MHTT
Literature
ReviewFocusGroup
ClinicalAdvisory
Panel
ModifiedDelphi Panel
FinalList of
Triggers
• Review of adverse events studies in mental health settings across the world
• Review of existing trigger tools
• Local adverse events studies/ reports
Development of MHTT
Literature Reviews
FocusGroup
ClinicalAdvisory
Panel
ModifiedDelphi Panel
FinalList of
Triggers
• Multidisciplinary focus group was formed to give input into the development of triggers
• Determined priority areas for trigger development based on AEs specific to mental health setting
Development of MHTT
Literature Reviews
FocusGroup
ClinicalAdvisory
Panel
ModifiedDelphi Panel
FinalList of
Triggers
• Advice on important AEs that matters in MH setting
• Advice on potential triggers that may identify those AEs
Development of MHTT
Literature Reviews
FocusGroup
ClinicalAdvisory
Panel
4-PhaseDelphi Process
FinalList of
Triggers
• Delphi panel of experts (Multidisciplinary)
• To collate expert feedback in a structured manner and formulate a consensus judgement on the choice of triggers
• Initial List = 30 triggers• After Delphi Round 1 = 34 triggers
• After Delphi Round 2 = 38 triggers
• After Round 3 = 58 triggers
• After Round 4 = 50 triggers
Development of MHTT
Literature Reviews
FocusGroup
ClinicalAdvisory
Panel
ModifiedDelphi Panel
List ofTriggers
Development of MHTT
• List of Triggers = 50 • POC Trial planned to test out the trigger
list
• A manual of triggers, their descriptions, guidelines to identify them and potential AEs were prepared
Main Challenges
• Definition of Harm or AE in Mental Health• Need to conform to IHI Trigger Tool system• Commission vs Omission events• Near Misses vs Actual Harm• Psychological harm
General Care Triggers
LaboratoryTriggers
MedicationTriggers
Mental HealthTriggers
Code TriggersG1 Transfer to General Hospital/Medical WardG2 Code Blue/ Cardio-Pulmonary arrestG3 Patient fallG4 Fever (Temp reading >37.5 deg)G5 Infection during hospital stayG6 Pressure ulcerG7 Referrals for consultation for medical reasonsG8 Re-admission within 30 daysG9 Fits/ seizures
G10 Initiation of ( e.g. GCS) or increase in frequency of monitoring of parameters after admission (including BP,PR, RR, Temp )
G11 High BMI ( 30 or above)G12 DVT/PE following admission evidenced by
imaging and/or D-dimer test
G13 Use of urinary catheter
Triggers
General Care Triggers
LaboratoryTriggers
MedicationTriggers
Mental HealthTriggers
TriggersCode Triggers
L1 X ray / CT Scan / MRI/ UltrasoundL2 Abnormal ECGL3 Serum Sodium <130 mmol/LL4 Platelet count <50000L5 WBC <3.0 or Neutrophils <1.5L6 Serum lithium> 1.2 mmol/L L7 Valproic Acid > 200 mg/mlL8 phenytoin > 20mg/ mlL9 Carbamazepine > 10mg/ml
L10 Elevated Liver enzymes ALT or AST or GGT (> double the upper end of normal range)
L11 Rising Serum Creatinine L12 Raised serum Creatinine Kinase L13 Digoxin level > 2mg/mlL14 International Normalized Ratio INR > 6L15 Glucose < 3 mmol/L
General Care Triggers
LaboratoryTriggers
MedicationTriggers
Mental HealthTriggers
TriggersCode Triggers
M1 Rash / itchingM2 Thyroxine M3 Anti-cholesterol medication (eg..Statins) M4 Hypoglycaemics (eg. Metformin) M5 Abrupt discontinuation of medicationM6 Antibiotics/ antimicrobials M7 IV Epinephrine / Norepinephrine / Naloxone/
Esmolol / Flumezenil
M8 Laxatives/Rectal Suppository / Enema M9 Oral or Parenteral (IM/IV) Anticholinergics
(eg Benzhexol/Procyclidine/Cogentin/Benztropine)
M10 Anti-emetics ( eg Metoclopramide)M11 Anti-diarrheals (eg. Loperamide)M12 Anti-histamines (eg. Chlorphenaramine)M13 TetrabenazineM14 Analgesics/ Anti-inflammatory
(eg. Paracetamol/Ibuprofen)
M15 Over-sedation/drowsinessM16 Propranolol
General Care Triggers
LaboratoryTriggers
MedicationTriggers
Mental HealthTriggers
Triggers
Code TriggersMH1 Self-harm/ attempted suicide
MH2 Violence or physical aggression by patient
MH3 Physically or sexually assaulted by another patient
MH4 Transfer to Higher Level of Care in Psychiatry (High Dependency Psychiatric Care Unit or DAV ward)
MH5 Restraint use
MH6 Absconding or missing from the ward
• Is it usable? • Does it identify triggers and harm?• Is it time and resource efficient?• Does the definition of harm requires
modification?• Does it identify harms that are clinically
important?• Can fewer triggers have the same result?• New useful triggers?
MHTT-Proof Of Concept (POC) Trial
Sample = 140 (randomly chosen files of discharged patients)
• Excluded cases = 6
Cases excluded as defined in the criteria on length of inpatient stay- > 3 days - < 90 days
• Each file reviewed by two 1st level reviewers (nurse/pharmacist)
followed by 2nd level physician reviewers• Total cases reviewed = 134
Time to review each file = 20-30 min
Planning(Feb/Mar 13)
Preparation(Apr/May 13)
Dev of MHTT(Jun/Jul 13)
POC trial(Aug/Sep13)
MHTT-Proof Of Concept Trial
Triggers with Highest Count
M12 Anti-histamines (45)
G10 Initiation of (eg GCS) or increase in frequency of parameters monitoring (39)
M14 Analgesic / Anti-inflammatory (37)
M8 Laxative/ Rectal suppository (34)
MH5 Restraint Use (31)
MHTT Trial FindingsTriggers with Highest Count
Sensitivity for Individual Triggers (Top 5)
M8 Laxatives (0.38)
M14 Initiation of (eg GCS) or increase freq of parameters monitoring (0.35)
M5 Abrupt discontinuation of medication (0.29)
M8 Oral or Parenteral (IM/IV) Anticholinergics (0.26)
MH5 Restraint Use (0.21)
MHTT Trial FindingsSensitivity for Individual Triggers
MHTT Trial FindingsDifferent Triggers Same Harm … Examples
Harm Triggers
Tardive Dyskinesia, Facial Twitching
• M5 Abrupt discontinuation of medication• M9 Oral or Parenteral (IM/IV) Anticholinergics
(Benzhexol/Procyclidine/Cogentin or Benztropine)
Drug Allergy - Rash
• M1 Rash / Itching• M5 Abrupt discontinuation of medication• M12 Antihistamine
Bruises / Swelling- due to Restraint
• MH5 Restraint Use• MH2 Violence or Physical Aggression by Patient• M14 Analgesics/ Anti-inflammatory• MH2 Initiation of (eg GCS) or increase in frequency of
parameters monitoring
• Trigger– Cohen’s Kappa = 0.21
• Harm– Cohen’s Kappa = 0.48
No. of valid cases = 134
MHTT Trial FindingsInter-rater Reliability
Trigger list – Trial on case files with High Impact Harms in IMH
Post Trial – New Triggers
Incident Type New Triggers Identified that could lead to AE
Intended self harm
IM Haloperidol/ Lorazepam Concious Level Chart (CLC) Increased observation for potential suicide
(PS) after admission
Patient fall Reports of injury (Eg contusion /
haematoma) CLC
Further Development
• Consulation with Dr Carol Haraden (IHI)• Multiple rounds of further review on Trigger list through focus
group and consultation with Clinical Advisory Panel• Eliminated triggers that indicated same harm• Eliminated triggers that are unlikely to pick up serious harms• Combined triggers with common themes• Added new triggers• Renamed the triggers for easy identification---------------Current list - 26 triggers - Descriptive manual on definition and use - Consensus on Definition of Harm
Validation Study
• Sample:
• Reviewers: Each case reviewed by two non-physicians (pharmacist/nurse) and one physician (psychiatrist, registrar and above)
• Analysis: sensitivity, specificity, positive and negative predictive value of the tool.
• Inter-rater reliability between the raters
cases with AEs
cases without AEs
Thank You